Amarin Corporation PLC (AMRN)

1.420
-0.020(-1.39%)
After Hours
1.490
+0.070(+4.93%)
- Real-time Data
  • Volume:
    2,038,372
  • Day's Range:
    1.350 - 1.500
  • 52 wk Range:
    1.110 - 5.970

AMRN Overview

Prev. Close
1.44
Day's Range
1.35-1.5
Revenue
535.65M
Open
1.49
52 wk Range
1.11-5.97
EPS
-0.06
Volume
2,038,372
Market Cap
563.47M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,960,035
P/E Ratio
-
Beta
2.28
1-Year Change
-68.86%
Shares Outstanding
396,811,326
Next Earnings Date
Aug 03, 2022
What is your sentiment on Amarin?
or
Market is currently closed. Voting is open during market hours.

Amarin Corporation PLC News

  • Amarin Earnings, Revenue Miss in Q1
    • ByInvesting.com-

    Investing.com - Amarin (NASDAQ:AMRN) reported on Wednesday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Amarin announced...

  • Amarin Corp. Misses Q1 EPS by 6c
    • ByInvesting.com-

    Amarin Corp. (NASDAQ:AMRN) reported Q1 EPS of ($0.08), $0.06 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $94.63 million versus the consensus...

Amarin Corporation PLC Analysis

Amarin Corporation PLC Company Profile

Amarin Corporation PLC Company Profile

Employees
1000

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellSellStrong Sell
SummaryStrong BuyStrong BuyStrong SellStrong SellStrong Sell
  • 1.25/30 soon…and 🚀🚀
    0
    • There are some interesting articles and preprints on researchgate in regards to vascepa as a treatment for long covid
      0
      • whats happend?
        0
        • EU approval, nice
          1
          • Holding April 30 6.50 strike call options for EU approval!
            0
            • over 20 Dollar end of this year
              0
              • $8 this week
                0
                • https://www.investing.com/news/leerink-partners-stick-to-their-buy-rating-for-amarin-corporation-plc-2436922
                  0
                  • What Does champ mean
                    0
                    • https://investor.amarincorp.com/news-releases/news-release-details/amarin-receives-positive-chmp-opinion-icosapent-ethyl
                      0